Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06727565 · ClinicalTrials.gov registry record · Phase 2
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
A Phase 2 study of Head and Neck Squamous Cell Carcinoma, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06727565 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 100 participants, below the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT06727565, a Phase 2 study of Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Zimberelimab
- DRUG Domvanalimab
Study Locations (20)
Other
- Sichuan Cancer Hospital - Chengdu
- Zhejiang Cancer Hospital - Hangzhou
- Guangxi Medical University Cancer Hospital - Nanning
- Shanghai East Hospital - Shanghai
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan
- CHU de Bordeaux - Pessac
- Fondazione IRCCS Istituto Nazionale dei Tumori - Milan
- Istituto Nazionale Tumori Fondazione G. Pascale - Naples
- Sarawak General Hospital - Sarawak
- Hospital Universitario Virgen del Rocio - Seville
- Kaohsiung Medical University Chung-Ho Memorial Hospital - Kaohsiung City
- China Medical University Hospital - Taichung
- Taipei Veterans General Hospital - Taipei
Victoria
- Monash Health - Clayton
- Alfred Health - Melbourne
Missouri
- Siteman Cancer Center - St Louis
Tennessee
- Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research - Nashville
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
New South Wales
- Westmead Hospital - Sydney
South Australia
- ICON Cancer Center - Kurralta Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06727565
The ClinicalTrials.gov registry entry for NCT06727565 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (14% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT06727565 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Victoria, Missouri.
Frequently Asked Questions
What is clinical trial NCT06727565 about?
NCT06727565 is a clinical study titled "Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01". Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combinatio...
What is the current status of trial NCT06727565?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-02-18. Estimated completion is 2026-08.
What conditions does trial NCT06727565 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06727565?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Zimberelimab (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT06727565?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06727565 being conducted?
This trial has 20 study locations across Missouri, Tennessee, Texas, New South Wales, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.